These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 908036)

  • 1. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients.
    Sitar DS; Shaw DH; Thirlwell MP; Ruedy JR
    Cancer Res; 1977 Nov; 37(11):3981-4. PubMed ID: 908036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of fluorouracil in humans.
    MacMillan WE; Wolberg WH; Welling PG
    Cancer Res; 1978 Oct; 38(10):3479-82. PubMed ID: 688233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered plasma kinetics of 5-FU at high dosage in rat and man.
    Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE
    Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics.
    Cano JP; Rigault JP; Aubert C; Carcassonne Y; Seitz JF
    Bull Cancer; 1979; 66(1):67-74. PubMed ID: 420949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
    Heggie GD; Sommadossi JP; Cross DS; Huster WJ; Diasio RB
    Cancer Res; 1987 Apr; 47(8):2203-6. PubMed ID: 3829006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol metabolism and disposition in cancer patients.
    Walle T; Walle UK; Kumar GN; Bhalla KN
    Drug Metab Dispos; 1995 Apr; 23(4):506-12. PubMed ID: 7600920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
    Port RE; Edler L; Herrmann R; Feldmann U
    Ther Drug Monit; 1991 Mar; 13(2):96-102. PubMed ID: 2053130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.
    Frytak S; Moertel CG; Rubin J
    Cancer Treat Rep; 1984 Dec; 68(12):1427-31. PubMed ID: 6095996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin.
    Choi YH; Lee AK; Bae SK; Kim SO; Lee MG
    Biopharm Drug Dispos; 2005 Apr; 26(3):93-8. PubMed ID: 15674819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary pharmacokinetics of intravenous ciramadol in humans.
    Rosseel MT; Bogaert MG; Oosterlinck W
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):304-6. PubMed ID: 6547699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography.
    Finj C; Sadée W
    Cancer Chemother Rep; 1975; 59(2 Pt 1):279-86. PubMed ID: 1097091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.
    McDermott BJ; van den Berg HW; Murphy RF
    Cancer Chemother Pharmacol; 1982; 9(3):173-8. PubMed ID: 7160054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The blood and urine concentration of 5-fluorouracil in patients with pancreatic neoplasms].
    Smolianskaia AZ; Itin AB
    Vopr Onkol; 1975; 21(5):52-6. PubMed ID: 1210145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.